Stay updated on Nivolumab and Ipilimumab in ACC Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and Ipilimumab in ACC Clinical Trial page.

Latest updates to the Nivolumab and Ipilimumab in ACC Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoChange DetectedLocations section is reorganized under a general 'Locations' header and now lists Illinois as a study site, replacing the previous 'Illinois Locations' heading. The footer 'HHS Vulnerability Disclosure' link was removed and the revision label updated from v3.3.2 to v3.3.3.SummaryDifference0.2%

- Check20 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check41 days agoChange DetectedPublications section now clarifies that entries are automatically filled from PubMed and may not all pertain to the study. A revision tag 'Revision: v3.3.2' is displayed.SummaryDifference0.1%

- Check48 days agoChange DetectedRemoved a government funding–related notice stating information may not be up to date; study details on the page remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check63 days agoChange DetectedMinor formatting tweaks and updates to non-critical metadata were observed, and core study details such as title, NCT number, objectives, eligibility criteria, and primary outcomes remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check91 days agoChange DetectedUpdate includes a prominent operating-status notice and a version upgrade from v3.1.0 to v3.2.0. The core effect is informing users about possible delays and the current open status of the NIH Clinical Center.SummaryDifference2%

- Check98 days agoChange DetectedExpanded immune biology content and updated version to v3.1.0, replacing the previous v3.0.2.SummaryDifference0.7%

Stay in the know with updates to Nivolumab and Ipilimumab in ACC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and Ipilimumab in ACC Clinical Trial page.